Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01640522 · ClinicalTrials.gov registry record · NA

Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms

A NA study of Pancreatic Cancer and Hepatocellular Carcinoma, sponsored by University of Pittsburgh.

Completed
Registry status
NA
Development phase
261
Enrollment target
1
Study location

NCT01640522: Completed NA study of Pancreatic Cancer and Hepatocellular Carcinoma, sponsored by University of Pittsburgh.

NCT01640522 is a NA study of Pancreatic Cancer and Hepatocellular Carcinoma that has completed, run by University of Pittsburgh. The registered enrollment target is 261 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (33% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01640522, a NA study of Pancreatic Cancer and Hepatocellular Carcinoma, has completed, sponsored by University of Pittsburgh.

COMPLETED
Registry status
NA
Development phase
261 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.

Primary Outcome

Center for Epidemiological Studies-Depression scale

Interventions

  • OTHER Collaborative Care
  • OTHER Enhanced usual Care

Study Locations (1)

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Trial Details

FieldValue
Enrollment Target 261 participants
Start Date 2008-01
Est. Completion 2014-12
Phase NA
University of Pittsburgh

1,238 total trials

What the finished NCT01640522 record still lists

NCT01640522 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (33% lower).

The record links to 7 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Collaborative Care is the first listed.

NCT01640522 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT01640522 about?

NCT01640522 is a clinical study titled "Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms". The purpose of this study is to test the efficacy of a collaborative care intervention to manage cancer-related symptoms and improve health related quality of life in patients diagnosed with hepatobiliary carcinoma.

What is the current status of trial NCT01640522?

This trial is currently completed. It is a NA study. The enrollment target is 261 participants. The study started on 2008-01. Estimated completion is 2014-12.

What conditions does trial NCT01640522 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Hepatocellular Carcinoma, Colorectal Carcinoma, Liver Metastases, Bile Duct Cancer.

What interventions are being tested in trial NCT01640522?

The interventions under investigation include: Collaborative Care (OTHER), Enhanced usual Care (OTHER).

Who is sponsoring clinical trial NCT01640522?

This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01640522 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01640522's enrollment target sits among peer trials

261 55th of 278 higher than 224 of 278 other Pancreatic Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05124912 · 261 participants · NA

    REMASTer: REcurrent Brain Metastases After SRS Trial

  • NCT06559891 · 261 participants · NA

    THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

  • NCT03713268 · 262 participants

    Intraoperative OCT Guidance of Intraocular Surgery II

  • NCT06074380 · 262 participants · Phase 4

    Non Inferiority Trial Investigating Surfactants Administered Via MIST

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01640522, the US trial registry maintained by the National Library of Medicine. NCT01640522 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.